021-51111890
购物车（）
sales@molnova.cn
Tivozanib hydrochloride hydrate
CAS No. 682745-41-1
Tivozanib hydrochloride hydrate ( —— )
产品货号. M35722 CAS No. 682745-41-1
Tivozanib hydrochloride hydrate 是一种有效的、选择性的、具有口服活性的VEGFR 酪氨酸激酶 抑制剂，对 VEGFR-1、VEGFR-2、VEGFR-3的 IC50 值分别为 0.21、0.16、0.24 nM。Tivozanib hydrochloride hydrate 抑制肿瘤组织中的血管生成和血管通透性，并显示出抗肿瘤活性。Tivozanib hydrochloride hydrate 具有研究转移性肾细胞癌 (RCC) 的潜力。
纯度: >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| 规格 | 价格/人民币 | 库存 | 数量 |
| 5MG | ￥511 | 有现货 |
|
| 10MG | ￥743 | 有现货 |
|
| 25MG | ￥1190 | 有现货 |
|
| 50MG | ￥1786 | 有现货 |
|
| 100MG | ￥2574 | 有现货 |
|
| 500MG | ￥6102 | 有现货 |
|
| 1G | 获取报价 | 有现货 |
|
生物学信息
-
产品名称Tivozanib hydrochloride hydrate
-
注意事项本公司产品仅用于科研实验，不得用于人体或动物的临床与诊断
-
产品简述Tivozanib hydrochloride hydrate 是一种有效的、选择性的、具有口服活性的VEGFR 酪氨酸激酶 抑制剂，对 VEGFR-1、VEGFR-2、VEGFR-3的 IC50 值分别为 0.21、0.16、0.24 nM。Tivozanib hydrochloride hydrate 抑制肿瘤组织中的血管生成和血管通透性，并显示出抗肿瘤活性。Tivozanib hydrochloride hydrate 具有研究转移性肾细胞癌 (RCC) 的潜力。
-
产品描述Tivozanib hydrochloride hydrate is a selective and orally activeVEGFR tyrosine kinase inhibitor with IC50 of 0.21, 0.16, 0.24 nM for VEGFR-1, VEGFR-2, VEGFR-3, respectively. Tivozanib hydrochloride hydrate inhibits angiogenesis and vascular permeability in tumor tissues and shows antitumor activity. Tivozanib hydrochloride hydrate has the potential for the research of metastatic renal cell carcinoma (RCC).
-
体外实验Tivozanib hydrochloride hydrate inhibits the phosphorylation of VEGFR-1, VEGFR-2 and VEGFR-3.
-
体内实验Tivozanib hydrochloride hydrate (1 mg/kg; p.o.; 14 days) suppresses the development of CNV lesions and leds to a significant regression of established CNV, reducing the affected areas by 67.7%.
-
同义词——
-
通路Angiogenesis
-
靶点VEGFR
-
受体VEGFR
-
研究领域——
-
适应症——
化学信息
-
CAS Number682745-41-1
-
分子量509.34
-
分子式C22H22Cl2N4O6
-
纯度>98% (HPLC)
-
溶解度In Vitro:?DMSO 中的溶解度 : 250 mg/mL (490.83 mM; 超声助溶 )
-
SMILESO.Cl.COc1cc2nccc(Oc3ccc(NC(=O)Nc4cc(C)on4)c(Cl)c3)c2cc1OC
-
化学全称——
运输与储存
-
储存条件(-20℃)
-
运输条件With Ice Pack
-
稳定性≥ 2 years
参考文献
1. Motzer RJ, et al. Tivozanib versus sorafenib as initial targeted therapy for patients with metastatic renal cell carcinoma: results from a phase III trial. J Clin Oncol. 2013 Oct 20;31(30):3791-9.?
